Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Adam Stoten

Head of Technology Transfer, Life Sciences, Isis Innovation, University of Oxford

Adam joined Isis in the role of Deputy Head of Technology Transfer in 2013, with specific responsibility for commercialisation of life/medical science technologies originating from Oxford research, and for managing Isis’ partnership with OUHT. Adam has more than a decade’s experience in the pharma/biotech sector in commercial roles encompassing business development and licensing, new venture formation, product development, lobbying/advocacy and general management. Between 2010 and 2013 Adam worked as Deputy General Manager for the Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture between the University of Oxford and Emergent BioSolutions Inc, which conducted the first ever efficacy study of a new TB vaccine in infants. Adam first worked at Isis between 2005 and 2010 as a Project Manager and subsequently a Team Leader in the Technology Transfer Group, successfully managing a wide range of licensing deals and spin-outs spanning therapeutics, vaccines, diagnostics, research tools and software. Prior to 2005 he worked for a biotechnology consultancy undertaking due diligence and market research projects. Adam has a 1st Class Honours degree in biology and a PhD in immunology from the University of Nottingham.